Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SLC45A2-specific T Cells + Ipilimumab in Metastatic Uveal Melanoma
NCT03068624Phase 1Active, not recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Sep 2017
- Primary completion
- Dec 2022
- Modality
- TCR-Engineered T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of autologous cd8+ slc45a2-specific t lymphocytes in Uveal melanoma (UM), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoint: Maximum Tolerated Dose at 6 weeks. Started Sep 2017; status: active, not recruiting.
02
Drugs
autologous cd8+ slc45a2-specific t lymphocytes
03
Conditions
Uveal melanoma (UM)
Beyond the preview
Go deeper on NCT03068624.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03068624.